121 related articles for article (PubMed ID: 3799428)
1. Hemodynamic effects of hydralazine in infants with idiopathic dilated cardiomyopathy and congestive heart failure.
Artman M; Parrish MD; Appleton S; Boucek RJ; Graham TP
Am Heart J; 1987 Jan; 113(1):144-50. PubMed ID: 3799428
[TBL] [Abstract][Full Text] [Related]
2. Regression of myocardial cellular hypertrophy with vasodilator therapy in chronic congestive heart failure associated with idiopathic dilated cardiomyopathy.
Unverferth DV; Mehegan JP; Magorien RD; Unverferth BJ; Leier CV
Am J Cardiol; 1983 May; 51(8):1392-8. PubMed ID: 6682617
[TBL] [Abstract][Full Text] [Related]
3. Effects of hydralazine on pressure-volume and stress-volume relations in congestive heart failure secondary to idiopathic dilated cardiomyopathy.
Smucker ML; Sanford CF; Lipscomb KM
Am J Cardiol; 1985 Oct; 56(10):690-5. PubMed ID: 4050708
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic effects of hydralazine in infants with a large ventricular septal defect.
Beekman RH; Rocchini AP; Rosenthal A
Circulation; 1982 Mar; 65(3):523-8. PubMed ID: 6459891
[TBL] [Abstract][Full Text] [Related]
5. Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedipine and direct-acting agonism with hydralazine in chronic refractory congestive heart failure.
Elkayam U; Weber L; McKay CR; Rahimtoola SH
Am J Cardiol; 1984 Jul; 54(1):126-31. PubMed ID: 6741802
[TBL] [Abstract][Full Text] [Related]
6. Hydralazine therapy in severe chronic heart failure: inability of radionuclide left ventricular ejection fraction measurement to predict the hemodynamic response.
Goldberg MJ; Franklin BA; Rubenfire M; Kerin NZ; Willens HJ; Ruskin R
J Am Coll Cardiol; 1983 Nov; 2(5):887-93. PubMed ID: 6313788
[TBL] [Abstract][Full Text] [Related]
7. Hydralazine pharmacodynamics in the dog.
Kittleson MD; Hamlin RL
Am J Vet Res; 1983 Aug; 44(8):1501-5. PubMed ID: 6625299
[TBL] [Abstract][Full Text] [Related]
8. Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects.
Artman M; Parrish MD; Boerth RC; Boucek RJ; Graham TP
Circulation; 1984 May; 69(5):949-54. PubMed ID: 6705171
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction.
Nelson GI; Silke B; Forsyth DR; Verma SP; Hussain M; Taylor SH
Am J Cardiol; 1983 Nov; 52(8):1036-40. PubMed ID: 6637819
[TBL] [Abstract][Full Text] [Related]
10. Prenalterol in primary dilated cardiomyopathy: hemodynamic and angiographic evaluation.
Branzi A; Specchia S; Binetti G; Magelli C; Zannoli R; Magnani B
Eur Heart J; 1983 Apr; 4(4):252-8. PubMed ID: 6684041
[TBL] [Abstract][Full Text] [Related]
11. Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects.
Chatterjee K; Ports TA; Brundage BH; Massie B; Holly AN; Parmley WW
Ann Intern Med; 1980 May; 92(5):600-4. PubMed ID: 7386999
[TBL] [Abstract][Full Text] [Related]
12. Determinants of circulatory response to intravenous hydralazine in congestive heart failure.
Wilson JR; St John Sutton M; Schwartz JS; Ferraro N; Reichek N
Am J Cardiol; 1983 Aug; 52(3):299-303. PubMed ID: 6869277
[TBL] [Abstract][Full Text] [Related]
13. Acute hemodynamic effects of hydralazine in dogs with chronic mitral regurgitation.
Kittleson MD; Johnson LE; Oliver NB
J Am Vet Med Assoc; 1985 Aug; 187(3):258-61. PubMed ID: 4030462
[TBL] [Abstract][Full Text] [Related]
14. Detrimental effects of hydralazine in patients with chronic air-flow obstruction and pulmonary hypertension. A combined hemodynamic and radionuclide study.
Tuxen DV; Powles AC; Mathur PN; Pugsley SO; Campbell EJ
Am Rev Respir Dis; 1984 Mar; 129(3):388-95. PubMed ID: 6322627
[TBL] [Abstract][Full Text] [Related]
15. Effects of hydralazine on coronary blood flow and myocardial energetics in congestive heart failure.
Magorien RD; Brown GP; Unverferth DV; Nelson S; Boudoulas H; Bambach D; Leier CV
Circulation; 1982 Mar; 65(3):528-33. PubMed ID: 7055874
[TBL] [Abstract][Full Text] [Related]
16. [Hemodynamic effects of hydralazine in the cardiac insufficiency of non-obstructive myocardiopathy].
Pailloncy M; Fernandez F; Lelguen C; Datchary J; Ponsonnaille J; Gerbaux A; Gras H
Arch Mal Coeur Vaiss; 1979 Mar; 72(3):276-83. PubMed ID: 114138
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients.
Franciosa JA; Pierpont G; Cohn JN
Ann Intern Med; 1977 Apr; 86(4):388-93. PubMed ID: 848799
[TBL] [Abstract][Full Text] [Related]
18. Sublingual nifedipine: acute effects in severe chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy.
Miller AB; Conetta DA; Bass TA
Am J Cardiol; 1985 May; 55(11):1359-62. PubMed ID: 3993570
[TBL] [Abstract][Full Text] [Related]
19. The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure.
Rubin LJ; Handel F; Peter RH
Circulation; 1982 Jun; 65(7):1369-73. PubMed ID: 7074795
[TBL] [Abstract][Full Text] [Related]
20. Impact of left ventricular cavity size on survival in advanced heart failure.
Lee TH; Hamilton MA; Stevenson LW; Moriguchi JD; Fonarow GC; Child JS; Laks H; Walden JA
Am J Cardiol; 1993 Sep; 72(9):672-6. PubMed ID: 8249843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
